Briefly, 81 patients had HR (hormone receptor)-positive, HER2-negative breast carcinoma (74.3%), 10 out of 109 had HER2+ cancer (9.2%), and 18 out of 109 (16.5%) had TN cancer. This evidence concerns the gene ERBB2 and cancer.